Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 393

1.

Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center.

Fouad TM, Ueno NT, Yu RK, Ensor JE, Alvarez RH, Krishnamurthy S, Lucci A, Reuben JM, Yang W, Willey JS, Valero V, Bondy ML, Cristofinalli M, Shete S, Woodward WA, El-Zein R.

PLoS One. 2018 Sep 24;13(9):e0204372. doi: 10.1371/journal.pone.0204372. eCollection 2018.

PMID:
30248155
2.

Overall survival in older patients with cancer.

Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy D.

BMJ Support Palliat Care. 2018 Sep 22. pii: bmjspcare-2018-001516. doi: 10.1136/bmjspcare-2018-001516. [Epub ahead of print]

PMID:
30244203
3.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL.

Oncologist. 2018 Aug 23. pii: theoncologist.2017-0498. doi: 10.1634/theoncologist.2017-0498. [Epub ahead of print]

PMID:
30139837
4.

Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.

Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK.

Oncologist. 2018 Aug 23. pii: theoncologist.2018-0213. doi: 10.1634/theoncologist.2018-0213. [Epub ahead of print]

PMID:
30139836
5.

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT.

Clin Breast Cancer. 2018 Jul 10. pii: S1526-8209(18)30009-0. doi: 10.1016/j.clbc.2018.07.008. [Epub ahead of print]

PMID:
30077429
6.

Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy.

Stecklein SR, Park M, Liu DD, Valle Goffin JJ, Caudle AS, Mittendorf EA, Barcenas CH, Mougalian S, Woodward WA, Valero V, Sahin AA, Yang WT, Shaitelman SF.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):568-577. doi: 10.1016/j.ijrobp.2018.06.016. Epub 2018 Jun 19.

PMID:
29928946
7.

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT.

JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.

PMID:
29879283
8.

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA.

J Cancer. 2018 Apr 6;9(8):1437-1447. doi: 10.7150/jca.23969. eCollection 2018.

9.

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK.

Cancer. 2018 Jun 1;124(11):2299-2305. doi: 10.1002/cncr.31336. Epub 2018 Mar 26.

PMID:
29579338
10.

Neurocognitive deficits in older patients with cancer.

Edwards BJ, Zhang X, Sun M, Holmes HM, Ketonen L, Guha N, Khalil P, Song J, Kesler S, Shah JB, Tripathy D, Valero V, Champlin RE.

J Geriatr Oncol. 2018 Sep;9(5):482-487. doi: 10.1016/j.jgo.2018.02.010. Epub 2018 Mar 9.

PMID:
29530493
11.

The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy.

Seykora TF, Ecker BL, McMillan MT, Maggino L, Beane JD, Fong ZV, Hollis RH, Jamieson NB, Javed AA, Kowalsky SJ, Kunstman JW, Malleo G, Poruk KE, Soares K, Valero V 3rd, Velu LKP, Watkins AA, Vollmer CM Jr; Pancreas Fistula Study Group.

Ann Surg. 2018 Feb 27. doi: 10.1097/SLA.0000000000002714. [Epub ahead of print]

PMID:
29489483
12.

Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A Jr, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM.

Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.

PMID:
29465744
13.

Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.

Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, Woodward W, Valero V, Ueno NT, Bedrosian I, Babiera G.

Breast Cancer Res Treat. 2018 Jun;169(3):615-623. doi: 10.1007/s10549-018-4715-0. Epub 2018 Feb 19.

PMID:
29460033
14.

Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes.

Palau A, Garz AK, Diesch J, Zwick A, Malinverni R, Valero V, Lappin K, Casquero R, Lennartsson A, Zuber J, Navarro T, Mills KI, Götze KS, Buschbeck M.

Oncotarget. 2017 Dec 1;8(70):115002-115017. doi: 10.18632/oncotarget.22839. eCollection 2017 Dec 29.

15.

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.

Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B.

Invest New Drugs. 2018 Apr;36(2):299-306. doi: 10.1007/s10637-018-0564-2. Epub 2018 Jan 27.

PMID:
29374384
16.

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.

Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.

NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.

17.

Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.

Reddy SM, Barcenas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, Hortobagyi GN, Valero V.

Br J Cancer. 2018 Jan;118(1):17-23. doi: 10.1038/bjc.2017.379. Epub 2017 Dec 12.

18.

Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.

Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA Jr.

Support Care Cancer. 2018 May;26(5):1561-1568. doi: 10.1007/s00520-017-3962-7. Epub 2017 Dec 2.

PMID:
29197959
19.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D.

Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.

PMID:
29175149
20.

Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy.

Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V.

Ann Surg. 2017 Oct 23. doi: 10.1097/SLA.0000000000002573. [Epub ahead of print] No abstract available.

PMID:
29064904
21.

MacroH2A1.1 regulates mitochondrial respiration by limiting nuclear NAD+ consumption.

Posavec Marjanović M, Hurtado-Bagès S, Lassi M, Valero V, Malinverni R, Delage H, Navarro M, Corujo D, Guberovic I, Douet J, Gama-Perez P, Garcia-Roves PM, Ahel I, Ladurner AG, Yanes O, Bouvet P, Suelves M, Teperino R, Pospisilik JA, Buschbeck M.

Nat Struct Mol Biol. 2017 Nov;24(11):902-910. doi: 10.1038/nsmb.3481. Epub 2017 Oct 9.

22.

Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.

Chaoul A, Milbury K, Spelman A, Basen-Engquist K, Hall MH, Wei Q, Shih YT, Arun B, Valero V, Perkins GH, Babiera GV, Wangyal T, Engle R, Harrison CA, Li Y, Cohen L.

Cancer. 2018 Jan 1;124(1):36-45. doi: 10.1002/cncr.30938. Epub 2017 Sep 20.

PMID:
28940301
23.

Identification of an Optimal Cut-off for Drain Fluid Amylase on Postoperative Day 1 for Predicting Clinically Relevant Fistula after Distal Pancreatectomy: A Multi-Institutional Analysis and External Validation.

Maggino L, Malleo G, Bassi C, Allegrini V, Beane JD, Beckman RM, Chen B, Dickson EJ, Drebin JA, Ecker BL, Fraker DL, House MG, Jamieson NB, Javed AA, Kowalsky SJ, Lee MK, McMillan MT, Roses RE, Salvia R, Valero V 3rd, Velu LKP, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2017 Sep 21. doi: 10.1097/SLA.0000000000002532. [Epub ahead of print]

PMID:
28938266
24.

Risk factors for falls in older patients with cancer.

Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJ.

BMJ Support Palliat Care. 2018 Mar;8(1):34-37. doi: 10.1136/bmjspcare-2017-001388. Epub 2017 Aug 31.

PMID:
28860112
25.

Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy: Analysis of 2026 Resections From the International, Multi-institutional Distal Pancreatectomy Study Group.

Ecker BL, McMillan MT, Allegrini V, Bassi C, Beane JD, Beckman RM, Behrman SW, Dickson EJ, Callery MP, Christein JD, Drebin JA, Hollis RH, House MG, Jamieson NB, Javed AA, Kent TS, Kluger MD, Kowalsky SJ, Maggino L, Malleo G, Valero V 3rd, Velu LKP, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2017 Aug 29. doi: 10.1097/SLA.0000000000002491. [Epub ahead of print]

PMID:
28857813
26.

Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index.

Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP, Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJ.

J Geriatr Oncol. 2018 Jan;9(1):81-83. doi: 10.1016/j.jgo.2017.07.012. Epub 2017 Aug 24. No abstract available.

PMID:
28844850
27.

A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer.

Woodward WA, Fang P, Arriaga L, Gao H, Cohen EN, Reuben JM, Valero V, Le-Petross H, Middleton LP, Babiera GV, Strom EA, Tereffe W, Hoffman K, Smith BD, Buchholz TA, Perkins GH.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):777-783. doi: 10.1016/j.ijrobp.2017.04.030. Epub 2017 May 3. Erratum in: Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):497.

PMID:
28843370
28.

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V.

Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Review.

29.

Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies.

Ecker BL, McMillan MT, Maggino L, Allegrini V, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Bloomston M, Callery MP, Christein JD, Dickson E, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Salem RR, Soares KC, Valero V 3rd, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

J Gastrointest Surg. 2018 Jan;22(1):68-76. doi: 10.1007/s11605-017-3547-2. Epub 2017 Aug 24. No abstract available.

PMID:
28840459
30.

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.

Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK.

J Cancer. 2017 Jul 5;8(11):2004-2009. doi: 10.7150/jca.18196. eCollection 2017.

31.

Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated?

Candelaria RP, Hansakul P, Thompson AM, Le-Petross H, Valero V, Bassett R, Huang ML, Santiago L, Adrada BE.

Am J Surg. 2018 Apr;215(4):693-698. doi: 10.1016/j.amjsurg.2017.06.032. Epub 2017 Jul 1.

PMID:
28712671
32.

Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions.

Poruk KE, Valero V 3rd, He J, Ahuja N, Cameron JL, Weiss MJ, Lennon AM, Goggins M, Wood LD, Wolfgang CL.

Pancreas. 2017 Aug;46(7):943-947. doi: 10.1097/MPA.0000000000000869.

PMID:
28697136
33.

Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation.

Shafaee MN, Salahudeen AA, Valero V.

J Oncol Pract. 2017 Aug;13(8):555-556. doi: 10.1200/JOP.2016.020198. Epub 2017 Jul 5. No abstract available.

PMID:
28678590
34.

Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy.

Ecker BL, McMillan MT, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Dickson EJ, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Javed AA, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Poruk KE, Salem RR, Schmidt CR, Soares K, Stauffer JA, Valero V, Velu LKP, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2018 Apr;267(4):608-616. doi: 10.1097/SLA.0000000000002327.

PMID:
28594741
35.

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A Jr, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT.

Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313.

PMID:
28549010
36.

Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.

Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A Jr, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM.

JAMA Surg. 2017 Jul 1;152(7):665-670. doi: 10.1001/jamasurg.2017.0562.

37.

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.

Castrellon AB, Pidhorecky I, Valero V, Raez LE.

Oncol Rev. 2017 Mar 17;11(1):324. doi: 10.4081/oncol.2017.324. eCollection 2017 Mar 3. Review.

38.

Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT.

Lancet Oncol. 2017 Apr;18(4):e228-e232. doi: 10.1016/S1470-2045(17)30192-4. Review.

39.

MacroH2A histone variants maintain nuclear organization and heterochromatin architecture.

Douet J, Corujo D, Malinverni R, Renauld J, Sansoni V, Posavec Marjanović M, Cantariño N, Valero V, Mongelard F, Bouvet P, Imhof A, Thiry M, Buschbeck M.

J Cell Sci. 2017 May 1;130(9):1570-1582. doi: 10.1242/jcs.199216. Epub 2017 Mar 10.

40.

Identification of frequent somatic mutations in inflammatory breast cancer.

Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT.

Breast Cancer Res Treat. 2017 Jun;163(2):263-272. doi: 10.1007/s10549-017-4165-0. Epub 2017 Feb 27.

PMID:
28243898
41.

Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction.

Sandberg LJ, Clemens MW, Symmans WF, Valero V, Caudle AS, Smith B, Kuerer HM, Hsu L, Kronowitz SJ.

Plast Reconstr Surg. 2017 Mar;139(3):586e-596e. doi: 10.1097/PRS.0000000000003050.

PMID:
28234813
42.

Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.

Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG Jr, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D.

Cancer. 2017 Jul 1;123(13):2422-2431. doi: 10.1002/cncr.30618. Epub 2017 Feb 15.

43.

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN.

J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30.

44.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL.

JAMA Oncol. 2017 Apr 1;3(4):509-515. doi: 10.1001/jamaoncol.2016.5281.

PMID:
27893038
45.

Clinical outcomes based on multigene profiling in metastatic breast cancer patients.

Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F.

Oncotarget. 2016 Nov 22;7(47):76362-76373. doi: 10.18632/oncotarget.12987.

46.

The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery.

Cata JP, Chavez-MacGregor M, Valero V, Black W, Black DM, Goravanchi F, Ifeanyi IC, Hernandez M, Rodriguez-Restrepo A, Gottumukkala V.

Reg Anesth Pain Med. 2016 Nov/Dec;41(6):696-703.

PMID:
27685344
47.

Predictors of left ventricular systolic function recovery in the setting of sinus tachycardia in patients with cancer.

Hassan SA, Yusuf SW, Sharma J, Khan J, Guindani M, Valero V, Chavez-McGregor M, Banchs J.

Echocardiography. 2017 Jan;34(1):29-36. doi: 10.1111/echo.13372. Epub 2016 Oct 21.

PMID:
27767228
48.

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ.

J Clin Oncol. 2016 Oct 10;34(29):3518-3528. doi: 10.1200/JCO.2016.66.6693.

49.

Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.

Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M.

Breast Cancer Res Treat. 2016 Sep;159(2):367-74. doi: 10.1007/s10549-016-3933-6. Epub 2016 Aug 13.

PMID:
27522517
50.

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.

Wheler JJ, Atkins JT, Janku F, Moulder SL, Stephens PJ, Yelensky R, Valero V, Miller V, Kurzrock R, Meric-Bernstam F.

Oncoscience. 2016 Jun 30;3(5-6):164-72. doi: 10.18632/oncoscience.307. eCollection 2016.

Supplemental Content

Loading ...
Support Center